Osborn Drugs owner wins NCPA independent pharmacist award
PHILADELPHIA The owner of an independent drug store based in Miami, Okla., was this year’s recipient of the Willard B. Simmons Independent Pharmacist of the Year award from the National Community Pharmacists Association.
William Osborn, a graduate of the University of Kansas City School of Pharmacy and the majority owner of Osborn Drugs since 1971, received the award at the NCPA’s annual convention and trade expo in Philadelphia. The Independent Pharmacist of the Year award recognizes an independent pharmacist for exemplary leadership and commitment to independent pharmacy and to his or her community.
“Willie Osborn is a very deserving recipient of the [Willard B. Simmons Independent Pharmacist of the Year] award because of the quality of services he provides patients, the impact he has on the community he lives in and his long-standing efforts to grow the ranks of independent community pharmacy owners by partnering with young entrepreneurs looking to break into the business,” said Joseph Harmison, NCPA president and Arlington, Texas, pharmacy owner.
The Independent Pharmacist of the Year award is sponsored by Upsher-Smith.
‘Picture This’ forums bring diabetes management awareness to public
PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.
The drug maker said Friday that, through its collaboration with the Entertainment Industries Council, it will host "Picture This" forums, which include an open discussion among diabetes stakeholders and the media to identify top diabetes communication challenges, explore strategies to address those priorities and strengthen community understanding about diabetes through news media and community affairs programs.
The forums will be held in Philadelphia on Oct. 22 and Seattle on Nov. 18.
"Novo Nordisk is proud to join EIC, the media and community leaders in Seattle and Philadelphia to explore ways to improve how diabetes is communicated about and understood by local citizens," said Tony Deluzio, senior medical director at Novo Nordisk. "As the prevalence of diabetes continues to be on the rise, bringing together those on the front line of diabetes care will open the potential to reduce the stigma associated with diabetes and empower those affected by the disease to lead full and productive lives."
Pfizer makes official tender offer for King
NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.
The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.
The offer expires at midnight on Nov. 19.